UNSPSC 51381503: Floctafenine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H17F3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O04HVX6A9Q, chemically known as 2,3-dihydroxypropyl n-(8-(trifluoromethyl)-4-quinolyl)anthranilate but generally known as floctafenine, which bears US NIH Compound Identifier 3360. European Medicines Agency schedules Floctafenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07645MIG.

UNSPSC 51381503 Floctafenine is a Commodity code that nominally describes a specific non-steroidal anti-inflammatory drug; however, recent state and local solicitations tagged with this code reveal minimal activity aligned with that product line. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems procurement, a Texas Health and Human Services Commission request for information on direct-to-manufacturer prescription programs, and a Minnesota cooperative purchasing alliance RFP for generic multi-source pharmaceuticals and over-the-counter products—span pharmaceutical purchasing and drug-related community health initiatives but do not center on floctafenine specifically. The issuing bodies include county health departments, state health and human services agencies, and regional cooperative purchasing alliances drawing participation from multiple state and local governments. The code shows limited specificity to the floctafenine product itself and appears to capture broader pharmaceutical procurement activity within state and local government health systems.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial contract term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor intelligence on direct-to-manufacturer prescription fulfillment capabilities for a proposed Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, contract effective July 1, 2026. The code shows limited recent activity specifically tied to floctafenine and appears misaligned with the opportunities currently posted under it.